Garrison Point Advisors’s Gilead Sciences GILD Stock Holding History

Garrison Point Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$252K	Buy	1,994 +2	+0.1%	+$264	0.1%	156
2026 Q1	$278K	Buy	1,992 +2	+0.1%	+$280	0.13%	144
2025 Q4	$244K	Sell	1,990 -1,698	-46%	-$206K	0.11%	150
2025 Q3	$409K	Buy	3,688 +2	+0.1%	+$227	0.17%	119
2025 Q2	$409K	Sell	3,686 -98	-3%	-$10.4K	0.19%	115
2025 Q1	$424K	Buy	3,784 +2	+0.1%	+$206	0.21%	108
2024 Q4	$349K	Buy	3,782 +2	+0.1%	+$180	0.17%	115
2024 Q3	$317K	Sell	3,780 -108	-3%	-$8.24K	0.2%	114
2024 Q2	$267K	Buy	3,888 +154	+4%	+$10.3K	0.18%	121
2024 Q1	$274K	Buy	3,734 +4	+0.1%	+$308	0.18%	130
2023 Q4	$302K	Buy	3,730 +3	+0.1%	+$233	0.21%	113
2023 Q3	$279K	Buy	3,727 +4	+0.1%	+$308	0.22%	116
2023 Q2	$287K	Buy	3,723 +3	+0.1%	+$239	0.21%	120
2023 Q1	$309K	Buy	+3,720	New	+$308K	0.23%	114

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Garrison Point Advisors's GILD Position: Q2 2026 in Review

Garrison Point Advisors increased its Gilead Sciences (GILD) stake by 0.1% in Q2 2026, buying an estimated $264 and bringing the position to 1,994 shares worth $252K. The position accounts for 0.1% of the portfolio, ranked #156.

Garrison Point Advisors first reported a position in GILD in Q1 2023 and has held it in 14 quarters since. The position peaked at $424K in Q1 2025. 2,278 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Garrison Point Advisors held 1,994 shares of Gilead Sciences worth $252K as of Q2 2026.
Garrison Point Advisors bought 2 Gilead Sciences shares in Q2 2026, an estimated $264.
Gilead Sciences made up 0.1% of Garrison Point Advisors's portfolio in Q2 2026, its #156 holding.
Garrison Point Advisors first reported a position in Gilead Sciences in Q1 2023 and has held it in 14 quarters since.
Garrison Point Advisors's Gilead Sciences position peaked at $424K in Q1 2025.
2,278 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Garrison Point Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.